New ‘weight-loss' drugs have lower impact in real life compared to clinical trial results: study
The results were published by researchers from the Cleveland Clinic, Ohio, U.S., in the peer-reviewed journal Obesity on June 10. Semaglutide and tirzepatide are FDA-approved medications for the treatment of type 2 diabetes and chronic weight management and are now also available in India.
Hamlet Gasoyan et al accessed electronic health record data from a large health system in Ohio and Florida to identify adults with overweight or obesity without type 2 diabetes who started with injectable semaglutide or tirzepatide between 2021 and 2023. They recorded early discontinuation (within 3 months) and late discontinuation (within 3–12 months) along with weight reduction. The researchers observed that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically-meaningful weight reduction in patients on these drugs.
Researchers also identified the factors associated with higher odds of achieving a weight loss of 10% or more, after one year of treatment — continuing medications or discontinuing late (vs. early), taking a high maintenance dosage, getting tirzepatide (vs. semaglutide) and were female (vs. male).
Commenting on the results of the study, V. Mohan, senior diabetologist, and chairman, Dr. Mohan's Diabetes Specialties Centre, Chennai, who has initiated patients on weight-loss drugs, says: 'The findings are not surprising because in a randomised clinical trial (RCT), there is constant follow up with the participants to continue with the drug regimen. On the other hand, in the real world, especially if patients buy their own medication, they often stop the drug. Even otherwise, compliance rates in real world are much poorer than in an RCT. The bottom line is that these drugs work as long as they are taken. That is how it is with most drugs, if you stop statins, for instance, cholesterol levels go up; if you stop anti-diabetic drugs or BP drugs, the sugar and BP go up.'
'A reality check'
Anoop Misra, who heads Fortis C-DOC Hospital for Diabetes and Allied Sciences in Delhi, who has also put his patients on these class of drugs, says: 'This study gives us a reality check of weight loss and blood sugar lowering effects of these drugs. It is important to note that discontinuation of such drugs is likely to be more in India, driven also by cost concerns. Non-compliance to diet and exercise are additional reasons to be considered in India which may cause lower weight loss.'
'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' said Dr. Gasoyan.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
11 hours ago
- Time of India
These hidden chemicals could sabotage your weight-loss efforts even after surgery. New research sounds alarm
Weight Regain Despite Surgery You Might Also Like: Weight Loss made easy with ChatGPT: 5 prompts for personalised fitness advice Why PFAS Are So Hard to Escape iStock PFAS, short for per- and polyfluoroalkyl substances, are human-made chemicals that combine carbon and fluorine atoms — a bond so strong they hardly break down, earning them the name 'forever chemicals.' Health Risks Beyond Weight A Modifiable Risk For decades, people have turned to strict diets, advanced weight-loss programs and even surgery to shed pounds. But a new study suggests an invisible enemy could be quietly sabotaging those efforts — 'forever chemicals' known as PFAS According to Health Day, researchers from the Keck School of Medicine at the University of Southern California report that teenagers with high levels of PFAS in their blood were significantly more likely to regain weight after undergoing bariatric surgery . The findings, published August 14 in the journal Obesity, raise alarm about how environmental exposure may undermine even the most aggressive weight-loss team tracked 186 adolescents who underwent bariatric surgery between 2007 and 2012, collecting blood samples beforehand to test for seven types of PFAS. They then monitored the participants' weight, body mass index (BMI) and waist size for up to five years after were striking. Those with the highest pre-surgery levels of certain PFAS compounds regained far more weight than those with lower levels. For example, teens with the highest levels of perfluorooctanesulfonate (PFOS) gained back about 47 pounds within five years, compared to 36 pounds among peers with the lowest PFOS exposure. Another PFAS chemical, perfluoroheptanesulfonic acid (PFHpS), was linked to an average yearly weight regain of 4.3 percent of body weight, compared to 2.7 percent in the low-exposure group.'These findings show a clear association between PFAS exposure and weight-related outcomes in bariatric surgery for adolescents,' lead author Brittney Baumert said in a news release. 'With the growing use of weight loss interventions, it's critical to understand how these chemicals may affect long-term success.'PFAS, short for per- and polyfluoroalkyl substances, are human-made chemicals that combine carbon and fluorine atoms — a bond so strong they hardly break down, earning them the name 'forever chemicals.' Since the 1940s, they've been used in everyday products: nonstick cookware, waterproof clothing, food wrappers, stain-resistant furniture and firefighting their persistence means they accumulate in the environment — and in our bodies. Drinking water is one of the largest sources of exposure in the United States, but they're also present in certain foods, cosmetics, and even dust from household studies have shown PFAS can disrupt hormones, impair metabolism and potentially contribute to weight gain. Now, research is beginning to link them to more specific outcomes, such as reduced effectiveness of weight-loss dangers of PFAS are not limited to waistlines. According to the Mayo Clinic, these chemicals have been linked to cardiovascular risks, especially in women. A recent American Heart Association study found that middle-aged women with higher PFAS levels were 70 percent more likely to develop high blood pressure than those with lower DeLisa Fairweather, a cardiovascular researcher at Mayo Clinic, explains that the effects can be compounded during menopause. 'When estrogen levels drop, the immune response changes, creating a more proinflammatory state,' she said. 'This can increase the risk for heart disease, atherosclerosis and stroke.'PFAS have also been detected in fish, dairy products and other foods, largely due to contaminated water and agricultural practices. Heating food in certain plastics can release PFAS into meals, prompting experts to recommend glass containers stresses that PFAS are a 'modifiable risk,' meaning exposure can be reduced through stronger regulations and personal choices. Policymakers are already considering stricter limits in drinking water, and researchers are calling for broader public USC team now plans to study whether PFAS could also affect the success of weight-loss drugs such as Ozempic or Zepbound, and whether they raise risks for metabolic disorders like type 2 diabetes or fatty liver disease.
Hindustan Times
a day ago
- Hindustan Times
FDA launches festive campaign to ensure food standards in the state
Mumbai: The Maharashtra Food and Drug Administration (FDA) on Monday launched a special campaign titled 'San Maharashtracha, Sankalp Anna Surakshathika Abhiyan,' to ensure hygiene and safety standards in the food sold during the upcoming festive seasons of Ganeshotsav, Eid, Navratri, Dussehra and Diwali in the state from August 11 to October 25. The campaign includes sudden inspections of eateries to keep in check food adulteration and ensure compliance with hygiene standards. The authority is also set to organise workshops to spread awareness about the standards to be met. FDA launches festive campaign to ensure food standards in the state The initiative was launched on Monday by the FDA secretary Dheeraj Kumar, along with FDA commissioner Rajesh Narvekar and senior department officials at the Yashwantrao Chavan Centre, followed by a training session for food professionals, aiming at educating traders on hygiene practices and legal compliance during the high-demand festive period. 'During festivals, the demand for sweets, modaks, faral and prasad skyrockets. This is when the risk of adulteration increases, as some traders may cut corners due to supply shortages,' FDA secretary Dheeraj Kumar said. Food businesses should strictly follow food safety standards, avoid malpractices, and ensure products are wholesome and hygienic, he added. 'We are increasing the number of food testing labs in the state. We are also working on providing manpower for the department.' FDA commissioner Rajesh Narvekar said, 'Adulteration is often detected when market demand exceeds supply. Through our training, we hope traders will comply fully with the law so that festivals can be celebrated without compromising health.' As part of the campaign, workshops on food hygiene will be conducted for those handling mandals, sweet manufacturers, and women's self-help groups that prepare festive foods. The authority will also carry out surprise inspections of food outlets, sweet shops, street vendors and production units across the state, including Mumbai, Pune, Nagpur and Chhatrapati Sambhajinagar.
Time of India
a day ago
- Time of India
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Novo Nordisk's stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal challenges fuel concerns over the Danish drugmaker's grip on the global diabetes and obesity market. Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Tired of too many ads? Remove Ads Intensifying Competitive Pressures Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. Tired of too many ads? Remove Ads Leadership Transition Amid Turbulence Legal and Regulatory Headwinds Analysts Split: Crash or Correction? Novo Nordisk: Denmark's global pharma giant Tired of too many ads? Remove Ads Key Innovative Advances Bolster Long-Term Outlook Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. So, Is This a 'Nokia Moment'? Summary Snapshot Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Investor Takeaways Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. FAQs: Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry Novo Nordisk lowered itsfrom. Operating profit (EBIT) growth was also trimmed to. The announcement triggered a, wiping out roughlyInvestors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting Nordisk's blockbuster drugsandhave faced growing headwinds:These trends highlight a: traditional competition and unregulated compounding pharmacies undermining pricing CEOstepped down on, passing the reins to. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.'Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around, although last year it briefly touched almost, putting it among the most valuable companies on the home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease short-term headwinds, Novo Nordisk is pursuing multiple growth avenues:These developments suggest Novo's, providing potential long-term exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded drugs and pharmacy compounding have reduced market share and investor confidence.
